Section Review: Oncologic, Endocrine & Metabolic: Immunoneuroendocrine therapy for endocrine tumours: recent developments

References

• WYBRAN J, APPLEBOOM T, FAMAEY JP, GOVAERTS A: Suggestive evidence for receptors for morphine and methionlne-enkephalin on normal human blood T-lymphocytes. J. Immunol. (1976) 123:1068–1071.
   Google Scholar
• RILEY V: Psychoneuroendocrine influences on immu-nocompetence and neoplasia. Science (1981) 212:1100–1109.
   PubMed Web of Science ®Google Scholar
• GROSSMAN CJ: Interactions between the gonadal ster-oids and the immune system. Science (1985) 227:257–261.
   PubMed Web of Science ®Google Scholar
• BLALOCK JE: Neuroimmunoendocrinology. Chem. Immunol. (1992) 52:1–95.
   Google Scholar
• HETIER E, AYALA J, DENEFLE P, BOUSSEAU A, ROUGE P, MALLAT M, PROCHIANTZ A: Brain macrophages synthe-size interleukin-1 and interleukin-1 mRNAs in vitro. J. Neurosci. Res. (1988) 21:391–397.
   PubMed Web of Science ®Google Scholar
• SPANGELO BL, MACLEOD RM, ISAKSON PC: Production of interleukin-6 by anterior pituitary cells in vitro. Endocrinology (1990) 126:582–586.
   PubMed Web of Science ®Google Scholar
• PANERI AE: Lymphocytes as a source of hormones and peptides. J. Endocrinol. Invest. (1993) 16:549–557.
   PubMed Web of Science ®Google Scholar
• BEUTLER B, CERAMI A: Cachectin: more than a tumour necrosis factor. New Engl. J. Med. (1987) 316:379–386.
   PubMed Web of Science ®Google Scholar
• PLATANIAS LC, VOGELZANG NJ: Interleukin-1: biology, pathophysiology, and clinical prospects. Am. J. Med. (1990) 89:621–628.
   PubMed Web of Science ®Google Scholar
• PLOTINIKOFF NP, MILLER GC: Enkephalins as iramuno-modulators. Int. J. Immunopharmacol. (1983) 5:437–441.
   PubMedGoogle Scholar
• DARDENNE M, SAVINO W: Prolactin-mediated cellular interactions in the thymus. Ann. NY Acad. Sci. (1994) 741:100–107.
   PubMed Web of Science ®Google Scholar
• IGUCHI H, KATO KI, IBAYASI-11 H: Age dependent reduc-tion in serum melatonin concentrations in healthy human subjects. J. Clin. Endocrinol. Metab. (1982) 55:27–29.
   PubMed Web of Science ®Google Scholar
• ATTANASIO A, BORRELLI P, GUPTA D: Circadian rhythmsIn serum melatonin from infancy to adolescence. J. Clin. Endocrinol. Metab. (1985) 61:388–390.
   PubMed Web of Science ®Google Scholar
• AXELROD J: The pineal gland: a neurochemical transducer. Science (1974) 184:1341–1348.
   PubMed Web of Science ®Google Scholar
• DI BELLA L, ROSSI MT, SCALERA G: Perspectives in pineal functions. Prog. Brain. Res. (1979) 92:475–478.
   Google Scholar
• BIRAU N, GOTTSCHALK J, PETERSEN U, MEYER C: Hormo-nal effects of intranasal melatonin application in essen-tial hypertension. Acta Endocrinol. (1982) 99:1534–1535.
   Google Scholar
• MAESTRONI GJM, CONTI A, PIERPAOLI W: Pineal mela-tonin, its fundamental brununoregulatory role in age-ing and cancer. Ann. NY Acad. Sci. (1988) 512:140–148.
   Google Scholar
• LISSONI P, PELIZZONI F, PEREGO M, FONDRINI G, GRUGNI G, GUZZALONI G, MORABITO F: A study of heart-pineal interactions: a trial natriuretic peptide response to melatonin administration in healthy hu-mans. J Pineal. Res. (1990) 9:167–170.
   PubMed Web of Science ®Google Scholar
• JANKOVIC BD, ISAKOVIC K, PETROVIC S: Effect of pinealectomy on immune reactions in the rat. Immunol-ogy (1970) 8:1–6.
   Google Scholar
• First report of the immunomodulatory activity of the pineal gland.
   Google Scholar
• REGELSON W, PIERPAOLI W: Melatonin: a rediscoveredantitumor hormone? Cancer Invest. (1987) 5:379–385.
   Google Scholar
• LISSONI P, BARNI S, TANCINI G, ROVELLI F, ARDIZZOIA A, CONTI A, MAESTRONI GJM: A study of the mechanisms Involved in the im,munostimulating action of the pineal hormone in cancer patients. Oncology (1993) 50:399-402. An interesting study of the immunomodulatory effects of melatonin in humans.
   Google Scholar
• MAESTRONI GJM, CONTI A, LISSONI P: Colony-stimulat-ing activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin 4. Cancer Res. (1994) 54:4740–4743.
   PubMed Web of Science ®Google Scholar
• LISSONI P, TISI E, BRIVIO F, ARDIZZOIA A, CRISPINO S, BARNI S, TANCINI G, CONTI A, MAESTRONI GJM: Modu-lation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin. Biol. Regul. Homeost. Agents (1991) 5:154–156.
   PubMed Web of Science ®Google Scholar
• ANTON-TAY F, DIAZ JL, FERNANDEZ-GUARDIOLA A: On the effect of melatonin upon brain. Its possible thera-peutic implications. Life Sci. (1971) 10:841–845.
   Google Scholar
• REITER RJ: The pineal gland: a regulator of regulators. se Frog. Psychobiol. Physiol. Psychol. (1980) 9:323-356. A review of the physiological role of the pineal gland.
   Google Scholar
• LISSONI P, RESENTINI M, MAURI R, MEDICI C, MORABITO F, ESPOSTI D, DI BELLA L, ESPOSTI G, ROSSI D, PARRAVI-CINI L, LEGNAME G, FRASCHINI F: Effect of an acute injection of melatonin on the basal secretion of hypo-physeal hormones in prepubertal and pubertal healthy subjects. Acta Endocrinol. (1986) 111:305–311.
   PubMedGoogle Scholar
• ARENDT J: Melatonin. Gun. Endocrinol. (1988) 29:205-229. An interesting review of the therapeutic implications of melatonin.
   Google Scholar
• ESPOSTI D, LISSONI P, MAURI R, ROVELLI F, ORSENIGO L, PESCIA S, VEGETTI G, ESPOSTI G, FRASCHINI F: The pineal gland-opioid system relation: melatonin-naloxone in-teractions in regulating Gil and LH releases in man. J Endocrinol. Invest. (1988) 11:103–106.
   PubMedGoogle Scholar
• BAUER W, BRINER U, DOEPHNER W, HALLER R, HUGUANIN R, MARBACH P, PETCHERT J: SMS 201-995: a very potent and selective octapeptkle analogue of so-matostatin with prolonged action. Life Sci. (1982) 31:1133–1140.
   PubMed Web of Science ®Google Scholar
• ANDERSON JV, BLOOM SR: Neuroendocrine tumors ofthe gut: long-term therapy with the somatostatin ana-logue SMS 201-995. Scand. J. Gastroenterol. (1986) 21:115–128.
   Web of Science ®Google Scholar
• REUBI JC, KVOLS L, KRENNING E, LAMBERTS SWJ: In vitro and in vivo detection of somatostatin receptors in human malignant tissues. Acta OncoL (1991) 30:463–468.
   PubMed Web of Science ®Google Scholar
• BAJETIA E, DI BARTOLOMEO M, ZILEMBO N, BOCHIC-CHIO AM: Medical treatment of neuroendocrine tu-mors. Tumori (1993) 79:380–388.
   PubMed Web of Science ®Google Scholar
• MORGANO A, PUPPO F, CRISCUOLO D, LOTT' G, INDIVERI F: Evening administration of alpha interferon: relation-ship with the circadian rhythm of cortisoL Med. Sci. Res. (1987) 11:615–616.
   Google Scholar
• ATKINS MB, GOULD JA, ALLEGRETTA M, LI JJ, DEMPSEY RA, RUDDERS RA, PARKINSON DR, REICHLIN S, MIER JW: Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J. Clin. Oncol. (1986) 4:1380–1391.
   PubMed Web of Science ®Google Scholar
• DENICOFF KD, DURKIN TM, LOTZE MT, QUINLAN PE, DAVIS CL, LISTWAK SJ, ROSENVERG SA, RUBINOW DR: The neuroendocrine effects of interleukin-2 treatment. J. Glitz. Endocrinol. Metab. (1989) 69:402–410.
   PubMed Web of Science ®Google Scholar
• LISSONI P, BARNI S, ARCHILI C, CATTANEO G, ROVELLI F, CONTI A, MAESTRONI GJM, TANCINI G: Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer. Anticancer Res. (1990)10:753–758.
   PubMed Web of Science ®Google Scholar
• ATKINS MB, SPARANO J, FISHER RI, WEISS GR, MARGOLINKA, FINK KI, RUBINSTEIN L, LOUIE A, MIER pv, GUCALP R, SOSMAN JA, BOLDT DH, DOROSHOW JH, ARONSON FR, SZNOL M: Randomized Phase II trial of high-dose inter- leukin-2 either alone or in combination with inter-feron alpha-2b in advanced renal cell carcinoma. J. Clin. Oncol. (1993) 11:661–670.
   PubMed Web of Science ®Google Scholar
• LISSONI P, BARNI S, ARDIZZOIA A, ANDRES M, SCARDINO E, CARDELLINI P, DELLA BITTA R, TANCINI G: A random-ized study of low-dose interleukin-2 subcutaneous im-munotherapy versus interleukin-2 plus inter-feron-alpha as first line therapy for metastatic renal cell carcinoma. Tumort (1993) 79:397–400.
   PubMed Web of Science ®Google Scholar
• KVOLS LK, BUCH M, MOERTEL CG: Treatment of metas-tatic islet carcinoma with a somatostatin analogue (SMS 201-995). Ann. Inter. Med. (1987) 107:162–165.
   PubMed Web of Science ®Google Scholar
• WANGBERG B, NILSSON O, THEODORSSON E: The effect of a somatostatin analogue on the release of hormones from human midgut carcinoid tumour cells. Br.J. Cancer (1991) 64:23–26.
   PubMed Web of Science ®Google Scholar
• OBERG K: Chemotherapy and biotherapy in neuroen-docrine tumors. Curr. Opin. Oncol. (1993) 5:110–120.
   PubMedGoogle Scholar
• SHEPHERD JJ, SENATOR GB: Regression of liver metasta-ses in patients with gastrin-secreting tumor treated with SMS 201-995. Lancet (1986) 11:546.
   Google Scholar
• CLEMENTS EC, ELIAS E: Regression of metastatic vipomawith somatostatin analogue SMS 201–995. Lancet (1985) i:874.
   Google Scholar
• VINIK A, MOATIARI AR: Use of somatostatin analog inmanagement of carcinoid syndrome. Dig. Dis. Sci. (1989) 34:145–149.
   Google Scholar
• KIRKWOOD JM, ERNSTOFF MS: Interferons in the treat-ment of human cancer. J. Clin. Oncol. (1984) 2:336–352.
   PubMed Web of Science ®Google Scholar
• ROTH MS, FOON KA: Current status of interferon ther-apy in oncology. Prog. Hematol. (1987) 15:19–38.
   PubMedGoogle Scholar
• FOON KA: Biological response modifiers: the new im-munotherapy. Cancer. Res. (1989) 49:1621–1639.
   PubMed Web of Science ®Google Scholar
• GRIMM EA, MAZUMDER A, ZHANG HZ, ROSENBERG SA: Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by inter-leukin-2-activated autologous human peripheral blood lymphocytes. J Exp. Med. (1982) 155:1823–1841.
   PubMed Web of Science ®Google Scholar
• LISSONI P, MAININI E, MAZZI C, CATTANEO G, BARNI S: A study of pineal-prolactin interaction: prolactin re-sponse to an acute melatonin injection in patients with hyperprolactinemia. J. EndocrinoL Invest. (1990)13:85–89.
   PubMed Web of Science ®Google Scholar
• OBERG K, NORHEIM I, AIM G: Treatment of malignant carcinoid tumors: a randomized controlled study of streptozotocin plus 5-FU and human leukocyte inter-feron. Eur. J. Cancer Clin. Oncol. (1989) 25:1475–1479.
   PubMedGoogle Scholar
• MOERTEL CG, RUBIN J, KVOLS LK: Therapy of metastatic carcinoid tumor and the malignant carcinoid syn-drome with recombinant leukocyte A interferon. J. Clin. Oncol. (1989) 7:865–868.
   PubMed Web of Science ®Google Scholar
• BARTSCH HH, STOCKMANN F, ARNOLD R, CREUTZFELDTW: Treatment of patients with metastatic carcinoid tumors by recombinant human interferon-alpha: re-sults from a Phase Il study. J. Cancer Res. Clin. Oncol. (1990) 29:950–951.
   Google Scholar
• GROHN P, KUMPULAINEN E, JAKOBSSON M: Response ofmednitary thyroid cancer to low-dose alpha-interferon therapy. Acta Oncol. (1990) 29:950–951.
   PubMed Web of Science ®Google Scholar
• JANSON E, RONNBLOM L, AHLSTORM H: Treatment withalpha-interferon versus alpha-interferon in combina-tion with streptozotocin and doxorubicin in patients with malignant carcinoid tumors: a randomized triaL Ann. Oncol. (1992) 3:635–638.
   Google Scholar
• SALTZ L, ICEMENY N, SCHWARTZ G, KELSEN D: A Phasetrial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer (1994) 74:958–961.
   PubMed Web of Science ®Google Scholar
• WEST 1X/H: Continuous infusion recombinant inter-leukin-2 (rIL-2) in adoptive cellular therapy of renal cancer and other malignancies. Cancer Treat. Rev. (1989) 16(Suppl. A):83–89.
   Google Scholar
• KRIGEL RE, PADOVIC-SHALLER KA, RUDOLPH AR, LITWINS, KONRAD M, BRADLEY EC, COMIS EL: A Phase I study of recombinant interleukin 2 plus recombinant beta-in-terferon. Cancer Res. (1988) 48:3875–3881.
   PubMed Web of Science ®Google Scholar
• PACIUCCI PA, HOLLAND JF, RYDER JS, KONEFAL RG, BEKESI GJ, ODCHIMAR R: Immunotherapy with inter-leukin-2 constant infusion with and without adoptive cell transfer and with weekly doxorubidn. Cancer Treat. Rev. (1989) 16(Suppl. A):67–75.
   Google Scholar
• JANSON E, AHISTORM M, ANDERSSON T: Octreotide andinterferon-alpha: a new combination for the treatment of malignant carcinoid tumours. Eur. J. Cancer (1992) 28A:1647–1650.
   PubMed Web of Science ®Google Scholar
• JOENSUU H, KATKA K, KUJARI H: Dramatic response ofa metastatic cardnoid tumour to a combination of interferon and octreotide. Acta Endocrinol. (1992) 126:184–185.
   PubMedGoogle Scholar
• LISSONI P, BARNI S, TANCINI G, ARDIZZOIA A, RICCI G, ALDEGHI R, BRIVIO F, TISI E, ROVELLI F, RESCALDANI R, QUADRO G, MAESTRONI G: A randomised study vvth subcutaneous low-dose interleukin-2 alone vs. inter-leukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br. J. Cancer (1994) 69:196–199.
   Google Scholar
• LISSONI P, BARNI S, TANCINI G, MAININI E, PIGLIAL F, MAESTRONI GJM, LEWINSKI A: Immunoendocrine ther-apy with low-dose subcutaneous htterleukin-2 plus melatonin of locally advanced or metastatic endocrine tumours. Oncology (1995) 52:163–166.
   PubMed Web of Science ®Google Scholar
• NERI B, FIORELLI C, MORONI F, NICITA G, PAOLETTI MC, PONCHIETTI R, RAUGEI A, SANTONI G, TRIPITELLI A, GRECHI G: Modulation of human lymphoblastoid inter-feron activity by melatonin in metastatic renal cell carcinoma. A Phase U study. Cancer (1994) 73:3015–3019.
   Google Scholar
• LISSONI P: Importance of interleultin-2 In cancer biotherapy. Adv. Cancer Then (1995) 8:1–4.
   Google Scholar
• LISSONI P, BARNI 5, ROVELLI F, BRIVIO F, ARDIZZOIA A, TANCINI G, CONTI A, MAESTRONI GJM: Neuroimmuno-therapy of advanced solid neoplasms with single eve-ning subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results. Eur.J. Can cer(1993) 29A:185–189.
   PubMed Web of Science ®Google Scholar
• First historical application of neuroinununomodulation in the treat-ment of human neoplasms.
   Google Scholar